DVL Shares dorsaVi Ltd
ASX · ASXLast in our picks 2026-09-27 — not in the current list; analysis below is from that screen
Clinical-stage nephrology biotech with upcoming trial milestones as key rerating triggers.
Signal breakdown
- ▸Upcoming ACTON trial milestones are meaningful near-term catalysts.
- ▸Above 50-day MA (+8.35%)
- ▾Near 52-week low (12.5% of range)
Is DVL a buy right now?
Trend: DVL is trading above the 50-day average (+0.00%), RSI 35 — neutral momentum, with a 3-month return of -23.08%.
Valuation & quality: dorsaVi Ltd trades on price-to-book 5.00; fundamentals show net margin 0.0%, return on equity -237.7%, revenue growth 1.0% year on year.
Our screen: BUY (score 3) — Clinical-stage nephrology biotech with upcoming trial milestones as key rerating triggers.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +33.30% | +25.00% | -20.00% | -25.00% | -33.30% | +50.00% | -33.30% |
Fundamentals
Technical signals
About dorsaVi Ltd
dorsaVi Ltd develops and sells motion analysis technologies in Australia, Europe, and the United States. It operates through three segments: Clinical, Workplace, and RRAM.
Sector: Technology · Industry: Scientific & Technical Instruments · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.